# Harmonix Fund

> Harmonix Fund is a VC fund backing Health Care and Biotechnology. See 48 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Palm Springs, United States
- Total investments: 48
- Last investment: Apr 2023
- Lead investor: 2%
- Last fund: Jun 2023
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/neue-fund/?viewAsMember=true
- X (Twitter): https://twitter.com/harmonixfund
- Website: https://neuefund.com/

Harmonix Fund is a VC fund in Palm Springs focused on Health Care and Biotechnology. Venture capital fund helping entrepreneurs launch exponential organizations generally with an impact or sustainability element.Passionate about creating positive impact at scale for humanity and the planet.Particular interest in human optimization, healthcare, and strategic interest in automotive and manufacturing technology.Specialties:HealthTech, Healthcare, DeepTech, impact, Startups, Early Stage, seed, Series A, VC, Angel investor, AutoTech, ManufacturingTech, Robotics, IoT, AgTech, connecting the dots.

## Contacts

5 contacts available for Harmonix Fund. Shizune tracks 5 team members at Harmonix Fund. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/neue-fund?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 18 | 38% |
| Biotechnology | 18 | 38% |
| Artificial Intelligence | 11 | 23% |
| Software | 8 | 17% |
| Medical | 6 | 13% |

48 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 14 | 29% |
| Series A | 10 | 21% |
| Funding Round | 7 | 15% |
| Series B | 5 | 10% |
| Venture - Series Unknown | 4 | 8% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 34 | 71% |
| Canada | 2 | 4% |
| Germany | 1 | 2% |
| Hong Kong | 1 | 2% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Anthony DeFeo | Managing Director of Marketing and Investor Relations | 0 | https://shizune.co/investors/profile/anthony-defeo-113e |
| Cofield Mundi | Partner | 0 | https://shizune.co/investors/profile/cofield-mundi |
| Katya Kohen | Partnership and Network Lead | 4 | https://shizune.co/investors/profile/ekaterina-dorozhkina |
| Krish Ramadurai | Partner | 10 | https://shizune.co/investors/profile/krish-ramadurai |
| Maximilian Winter | Founder | 0 | https://shizune.co/investors/profile/maximilian-winter |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| SentiAR | SentiAR is digital health, software device company adding a new dimension to clinical practice in interventional procedures. Spun out of Washington University, we are developing the first 3D visualization platform using real-time holography of the patient's anatomy and catheter location, "floating" over the patients, with a goal toprovide the clinician and patient a faster, safer delivery of care.SentiAR’s mission is to transform the experience for both patient and clinician in interventional procedures with a 3D augmented reality platform featuring real-time holographic visualization of the patient’s actual anatomy, “floating” over the patient.The visualization is fully controllable “hands-free” by the clinician, providing an ergonomic breakthrough for the treatment and analysis of cardiac arrhythmias within an interventional catheter lab environment. SentiAR is developing the platform for eventual FDA submission. | $8.5M | Series B | Apr 11, 2023 |  |
| ATLAS Space Operations | ATLAS Space Operations is the Satellite Communications as a Service Getting Your Data, Faster | $26M | Series B | Aug 25, 2022 |  |
| Caresyntax | Caresyntax is a digital surgery platform that enables OR teams to predict and improve surgical performance. Its enterprise-grade digital surgery platform delivers insights to improve patient outcomes by using proprietary software and AI to analyze large volumes of video, audio, images, device data, clinical, and operational data in and around theOR.Caresyntax insights help surgeons benchmark and improve their care, hospital administrators use surgical resources more efficiently, medical device companies advance better products, and insurance companies understand risk and devise more tailored policies. The software is used in more than 4,000 operating rooms worldwide, has supported more than 30,000 surgeons, and improved care for more than 2 million patients. | $130M | Series C | Sep 16, 2021 |  |
| Sorcero | Sorcero provides an AI-powered intelligence platform tailored for life sciences teams. It enables medical affairs, safety, scientific communications, and medtech groups to extract meaningful insights from unstructured and structured biomedical data. Through its Instant Insights Engine and agentic AI framework, users can ask conversational questionsand quickly receive medically validated answers linked to their source material. Sorcero also offers tools for literature monitoring, safety signal detection, and converting complex science into clear, plain-language summaries. The platform supports compliant workflows by providing auditability, AI guardrails, and access controls to manage insights securely. | $10M | Series A | Sep 16, 2021 |  |
| Attivare Therapeutics | Attivare Therapeutics develops biomaterial vaccines to facilitate multiple applications. | $6M | Seed | Aug 17, 2021 |  |
| xCures | The convergence of genomics, precision medicine, and AI have created an unprecedented moment in the world of oncology. But the drug-centric way in which treatments are developed and the haphazard way in which knowledge about those treatments is captured and delivered to the point of care does not serve patients well. xCures is changing that, withan AI-based precision oncology platform that tightly integrates cancer research and care.The xCures platform runs a perpetual trial that captures Real World Evidence (RWE) to continuously learn from all patients, on all treatments, all the time. It coordinates treatment recommendations across all patients and institutions to match patients with the treatments that work. And it packages RWE for use by stakeholders across oncology, slashing the time and cost of drug development and saving lives. | $12.7M | Series A | Jun 23, 2021 |  |
| Strateos | Strateos automates chemistry, biology, and tissue analysis into closed-loop robotic labs that accelerate drug discovery programs. Through a combination of best-in-class robotics and control systems, advanced software for imaging and analytics, and remote cloud laboratories, they enable pharmaceutical partners to more rapidly and efficientlydiscover new drug candidates.Born of a merger between Transcriptic and 3Scan, Strateos combines the strengths of those companies to amplify their impact and accelerate drug discovery. Transcriptic developed the first robotic cloud laboratory platform for on-demand life science research, which is currently in use at several top pharmaceutical and biotechnology companies. 3Scan combined automation, machine learning and computer vision to extract spatial data from tissue samples and create detailed 3D representations as well as quantitative analysis of complex anatomical structures. Now these two portfolios will be combined to offer a suite of technologies for accelerating drug discovery and early development.By expressing life science methods as data, infrastructure virtualization will become possible. "Science-as-a-Service" will power the next generation of discovery, driven by huge efficiencies of both time and money.Transcriptic was founded in 2012 to create a better way to get lab work done. Tired of spending endless hours at the bench pretending to be slow, error-prone robots, they set out to build a modern solution to the day-to-day process of wet lab biology.Drawing on deep computer science and electrical engineering backgrounds in addition to life science, Strateos was born: a meticulously optimized, technology-enabled remote lab. Using state-of-the-art automation and control technology, and an emphasis on user experience and usability, they are working on building a stark contrast to the long, complicated sales process, high prices, and slow turnarounds of traditional CROs.They are working hard to build a great company that can be a true partner for your lab for a long time, progressively enabling ever greater levels of productivity and efficiency. They are scientists building for scientists. | $56.1M | Series B | Jun 08, 2021 |  |
| Sana Health | Sana Health is an audio-visual neuromodulation device, that provides anxiety relief on-demand - multiple applications in pain and mental health, 2 pivotal studies are underway in Fibromyalgia (FDA designated breakthrough device) and Neuropathic Pain. Anxiety and PTSD trials starting in Q2 2022, DoD grant for PTSD.SOSV, Founders Fund, Noetic Fund,Harmonix, Dreamit, Esplanade, Bridge Builders Collective, Menlo Ventures. |  | Venture - Series Unknown | May 26, 2021 |  |
| Scribe Biosciences | Our fundamental technology, Printed Droplet Microfluidics (PDM), is a flexible and reconfigurable fluid handling system to perform picoliter-scale manipulations. By leveraging fluorescence-activated microfluidic droplet sorting and a specialized substrate, PDM enables the flexible and deterministic handling of single cells and fluid aliquots atextremely high throughputs. ​ | $2.4M | Venture - Series Unknown | May 12, 2021 |  |
| Scribe Biosciences | Our fundamental technology, Printed Droplet Microfluidics (PDM), is a flexible and reconfigurable fluid handling system to perform picoliter-scale manipulations. By leveraging fluorescence-activated microfluidic droplet sorting and a specialized substrate, PDM enables the flexible and deterministic handling of single cells and fluid aliquots atextremely high throughputs. ​ | $500K | Angel | May 12, 2021 |  |

10 of 48 investments shown.

## Co-investors
- [Harmonix Fund](https://shizune.co/investors/profile/harmonix-fund) — VC Fund, 24 deals together
- [DCVC](https://shizune.co/investors/profile/data-collective) — VC Fund, 3 deals together
- [Prime Movers Lab](https://shizune.co/investors/profile/prime-movers-lab) — VC Fund, 3 deals together
- [VCapital](https://shizune.co/investors/profile/vcapital) — VC Fund, 3 deals together
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund, 2 deals together
- [ANIMO Ventures](https://shizune.co/investors/profile/animo-ventures) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Harmonix Fund invest in?

Harmonix Fund invests primarily in Health Care, Biotechnology and Artificial Intelligence startups, most often at Seed and Series A stage. Most of the 48 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Harmonix Fund?

Public channels for Harmonix Fund include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Harmonix Fund?

The team at Harmonix Fund includes Anthony DeFeo (Managing Director of Marketing and Investor Relations), Cofield Mundi (Partner) and Katya Kohen (Partnership and Network Lead). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co